You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth

 

Online download statistics by month:

Online download statistics by month: June 2020 to July 2025

AbstractFullPdf
Jun 202023223193
Jul 202013713948
Aug 2020818148
Sep 202010710746
Oct 2020737328
Nov 202010210364
Dec 2020959540
Jan 202112212257
Feb 202114114159
Mar 202118318365
Apr 202112812843
May 2021939348
Jun 2021999973
Jul 202110810891
Aug 2021118120159
Sep 202110310375
Oct 202113613789
Nov 202110911062
Dec 202110911059
Jan 202210711356
Feb 2022859150
Mar 2022203209101
Apr 202216216678
May 202216316895
Jun 202218118480
Jul 202211512751
Aug 202215015452
Sep 202216516893
Oct 202218118590
Nov 2022143146108
Dec 202213313754
Jan 202315715758
Feb 202325425567
Mar 202322422975
Apr 202315215256
May 202316716966
Jun 202315916070
Jul 202317417858
Aug 202314014159
Sep 202314014033
Oct 202314614943
Nov 202317217356
Dec 202314014181
Jan 202410811061
Feb 202413613760
Mar 2024181181123
Apr 2024180181104
May 202416316472
Jun 202417117369
Jul 202420521166
Aug 202413413663
Sep 202413513791
Oct 202417817877
Nov 202417818190
Dec 2024221229111
Jan 2025233233112
Feb 2025229230111
Mar 202516616994
Apr 202518818987
May 202514114281
Jun 2025989939
Jul 2025110
Total913592564388